Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

JOINN Laboratories China Purchases Instem’s Preclinical Software Suite

Published: Wednesday, January 30, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
Leading Chinese CRO selects Version 9 of Provantis integrated preclinical software to automate study processes at Beijing and Suzhou sites.

Instem, a leading provider of IT solutions to the global early development healthcare market, announced that JOINN Laboratories (JOINN), one of China’s largest providers of preclinical services, has purchased the Provantis preclinical solution suite following a comprehensive competitive evaluation of vendors.

Established in 1995, JOINN provides drug screening, efficacy studies, pharmacokinetics studies, safety evaluations, clinical trials and final drug registration services with a heightened focus on quality. JOINN supports clients from more than 20 provinces across China, Japan and Europe, and within the United States is providing international clients with technical consulting services for FDA drug registration.

Key facts
•    Comprehensive suite of integrated Provantis modules purchased for up to 200 users; including In-Life, Reproductive Toxicology, Pathology, Dispense, Clinical Pathology and Data Import
•    JOINN to implement Provantis 9; the latest version of Instem’s market leading preclinical software solution
•    Competitive evaluation conducted; Instem selected for established presence within China, combined with global market leadership
•    Provantis offers JOINN compliance to national and western standards with dual language operation
•    A range of professional services purchased to facilitate quicker, smoother implementation and faster return on investment

Dr. Yuxia Feng, President & CEO, JOINN commented “We were looking for a market leading solution to support our long term growth plans and we are confident that our investment in Provantis will help to deliver demonstrable efficiency improvements within our R&D facilities. We are looking forward to a long and successful partnership with Instem.”

Phil Reason, President & CEO Instem said “We are delighted to welcome JOINN to the Instem client community. Their order for 200 licensed users adds significantly to the leadership position we already enjoy in the China market and is a further indication of the long term growth potential in what is already the third largest pharmaceutical market in the world.”

As the first western toxicology/pathology software supplier to enter the Chinese market, Instem officially deployed its first China-based system in one of the largest and most advanced vivariums during 2006. Acknowledging analyst projections that the People’s Republic of China (PRC) is on pace to becoming the second largest pharmaceutical market in the world, Instem established a full-service office in Shanghai, recruited local staff and has localized the Provantis product suite into Mandarin Chinese. Instem is supporting international organizations and domestic laboratories exclusively serving the PRC using on-site systems as well as their SaaS delivery model from a professionally managed data center based in Shanghai.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!